Pharmaceuticals News and Research

RSS

Physicists use diamonds to detect early-stage cancerous tumours

Physicists from the University of Sydney have devised a way to use diamonds to identify cancerous tumours before they become life threatening.

12 Oct 2015

AGS releases updated, expanded Beers Criteria to improve medication use in older adults

The American Geriatrics Society today released its second updated and expanded Beers Criteria--lists of potentially inappropriate medications for older adults who are not receiving hospice or palliative care, and one of the most frequently cited reference tools in the field of geriatrics.

12 Oct 2015

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

Safety and immunogenicity clinical trial of Ebola vaccine regimen starts in Sierra Leone

Johnson & Johnson today announced the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies.

9 Oct 2015

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition products, Contract Manufacturing, and iForce Nutrition ("iForce"), one of the fastest-growing Sports Nutrition companies in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire iForce.

9 Oct 2015

New national report on use of antiviral drugs to treat, prevent influenza

A major new national report into the use of antiviral drugs (neuraminidase inhibitors) to treat and prevent influenza has drawn heavily on two pieces of research undertaken at The University of Nottingham.

9 Oct 2015

Research on investigational menopause drug wins first prize

Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced it received top honors for its research on investigational drug lasofoxifene at the 26th annual North American Menopause Society (NAMS) meeting in Las Vegas last week.

9 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

8 Oct 2015

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse intraoral technology platform, today announced positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD).

8 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a regulatory update on Zalviso (sufentanil sublingual tablet system) intended for the management of moderate-to-severe acute pain in adult patients in the hospital setting.

8 Oct 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.

8 Oct 2015

Wake Forest Baptist Medical Center announces creation of Technology Development Program

Wake Forest Baptist Medical Center today announced the creation of a Technology Development Program, a $15 million program to develop the ideas, discoveries and inventions of the faculty and staff of the Medical Center into life science technologies having the potential to benefit patients in the community and worldwide.

8 Oct 2015

New book suggests ways to reduce medical reversals

Medical reversal—when accepted medical interventions are abandoned because they are found to be ineffective—is the "most important problem in medicine today," according to the authors of a new book: Ending Medical Reversal.

8 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

New white paper on active-ULD performance from CSafe Global

CSafe Global, the world's largest producer of actively controlled mobile refrigeration units for biopharmaceutical and healthcare applications, has released a white paper highlighting the problems and risk associated with using poorly maintained container stock.

7 Oct 2015

VWR announces acquisition of Purification Technologies

VWR, a leading, global, independent provider of laboratory products, services and solutions, announced today that it has acquired Purification Technologies Inc., a specialty solvent company that performs high volume purification of selected high purity solvents. This acquisition will enhance VWR's growing laboratory and production chemical manufacturing portfolio to better support its laboratory and biopharmaceutical manufacturing customers.

7 Oct 2015

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

Pharmaceuticals News and Research

Physicists use diamonds to detect early-stage cancerous tumours

AGS releases updated, expanded Beers Criteria to improve medication use in older adults

FDA awards research grants to boost product development for patients with rare diseases

Safety and immunogenicity clinical trial of Ebola vaccine regimen starts in Sierra Leone

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

New national report on use of antiviral drugs to treat, prevent influenza

Research on investigational menopause drug wins first prize

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Wake Forest Baptist Medical Center announces creation of Technology Development Program

New book suggests ways to reduce medical reversals

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

New white paper on active-ULD performance from CSafe Global

VWR announces acquisition of Purification Technologies

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Event guide: World ADC Asia eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring